Tirzepatide 10mg

Tirzepatide is a synthetic peptide studied as a dual incretin receptor agonist that targets both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Published clinical research has examined tirzepatide most directly in type 2 diabetes and obesity, where studies have reported significant effects on glycaemic control, body weight, and cardiometabolic markers in selected populations (Frias et al., 2021; Jastreboff et al., 2022). In research settings, tirzepatide is commonly explored in relation to metabolic regulation, appetite signalling, insulin sensitivity, and body composition. Supplied as a lyophilised peptide, this product is intended strictly for laboratory research use only. Tirzepatide is approved in the U.S. in branded forms for type 2 diabetes and chronic weight management, but any non-approved compounded or research-market versions are not equivalent to FDA-approved products. Reported adverse effects in trials and prescribing information include mainly gastrointestinal events, with boxed warnings and contraindications related to thyroid C-cell tumour risk in rodents.